Search

Your search keyword '"Swoboda, Kathryn J."' showing total 564 results

Search Constraints

Start Over You searched for: Author "Swoboda, Kathryn J." Remove constraint Author: "Swoboda, Kathryn J."
564 results on '"Swoboda, Kathryn J."'

Search Results

2. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

3. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

5. Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy

8. Exercise training reverses cancer-induced oxidative stress and decrease in muscle COPS2/TRIP15/ALIEN

10. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment

11. Correction: Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry

12. Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

13. Circulating metabolites and physical performance are predictors of overall survival in metastatic lung cancer patients

15. Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype

16. Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions.

22. Base editing as a genetic treatment for spinal muscular atrophy

25. Author Correction: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language

26. Author Correction: CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language

27. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study.

28. CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language

30. De novo variants in genes regulating stress granule assembly associate with neurodevelopmental disorders

31. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients

32. Clinical trial of L‐Carnitine and valproic acid in spinal muscular atrophy type I

34. Contributors

36. Natural history of infantile‐onset spinal muscular atrophy

37. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study

42. Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series

43. SMN-targeted therapeutics for spinal muscular atrophy: are we SMArt enough yet?

45. Clinical and genetic characterization of manifesting carriers of DMD mutations

46. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients

47. Cancer‐induced muscle atrophy is determined by intrinsic muscle oxidative capacity

50. Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45

Catalog

Books, media, physical & digital resources